IN8BIO, INC.

Clinical-stage biopharma developing gamma-delta T cell therapies for solid & hematological tumors.

INAB | US

Overview

Corporate Details

ISIN(s):: US45674E1091
LEI:
Country:: United States of America
Address:: EMPIRE STATE BUILDING, 10118 NEW YORK
Website:: https://www.in8bio.com
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

IN8BIO, INC. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell therapies for solid and hematological tumors. The company's proprietary DeltEx™ platform employs allogeneic, autologous, iPSC, and genetically modified approaches to develop novel cell therapies. A pioneer in the field, IN8BIO was the first company to advance genetically modified gamma-delta T cells into clinical trials. Its lead product candidates include INB-400 (Phase 2 for glioblastoma), INB-200 (Phase 1 for glioblastoma), and INB-100 (Phase 1 for leukemia), complemented by a portfolio of preclinical programs. The company's stated mission is to achieve "CANCER ZERO" by developing next-generation treatments for cancer patients.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all IN8BIO, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for IN8BIO, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for IN8BIO, INC. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
MedinCell S.A. Develops long-acting injectable therapies using proprietary technology to impact global health.	France	MEDCL
MEDINET Co., Ltd. A CDMO for cell therapy and regenerative medicine development & manufacturing.	Japan	2370
Medios AG Compounding patient-specific therapies and supplying specialty pharma for complex conditions.	Germany	ILM1
MEDIPOSTCO.,LTD. Develops cord blood stem cell therapies for osteoarthritis & infant lung disease, plus banking.	South Korea	078160
MediWound Ltd. Develops enzymatic therapies for non-surgical tissue repair in burns and chronic wounds.	United States of America	MDWD
Medizen Humancare Inc Co., Ltd Offers DTC genetic testing and genomic analysis for personalized disease risk prediction.	South Korea	236340
Medy-Tox Inc. Develops and markets botulinum toxins and dermal fillers for global aesthetic & therapeutic use.	South Korea	086900
MeiraGTx Holdings plc Develops genetic medicines for eye, salivary gland, and CNS disorders using gene regulation tech.	United States of America	MGTX
Meito Sangyo Co., Ltd. Produces food products and specialty chemicals for industrial and pharmaceutical applications.	Japan	2207
Merck & Co., Inc. A global biopharma developing innovative medicines, vaccines, and animal health products.	United States of America	MRK